Theravance Biopharma Inc

Theravance Biopharma (TBPH) was a special situation tied to a drug-related royalty stream following the failure of a Phase III drug trial. The company announced that a strategic review committee was considering all options to create value for shareholders. The manager believed the most likely outcome would be a sale of the company at a price somewhere between $17 and $25, but news of a sale came in near quarter end at the low end of this expected range, indicating a lack of confidence in the company's future prospects.

Theravance Biopharma, Inc. (TBPH) represents a compelling investment opportunity following a failed Phase III FDA trial, as the company is now a pile of cash with a royalty stream expected to generate ~$65M per year. With ~$400M in cash, $100M in 2026 milestones, and $2.6B in tax assets, the downside is well protected. The company is accelerating the work of a strategic review committee, indicating a potential sale of the royalty stream. Valuation estimates suggest a range of $17-$25, with shares purchased below $14. The expected resolution of this situation within 0-6 months presents a favorable risk-reward profile.

We initiated our position in Theravance on March 3, after the company announced a major corporate restructuring, including a complete exit from R&D and a 50% reduction in G&A headcount. Management expects these actions to reduce annual operating expenses by $70 million. Beginning in Q3 2026, Yupelri royalties, combined with interest income, are expected to generate $60-70 million of annual cash flow. With patent protection extending through April 2039, Yupelri represents a long-duration and growing cash flow stream. We estimate intrinsic value at $23 per share, or more than 60% upside from our cost basis of $13.80.